EU authorises Enhertu after surgery in patients with HER2-positive early-stage breast cancer

Several outlets report that the EU has approved Enhertu as an adjuvant therapy for residual disease in early-stage HER2-positive breast cancer, citing a 53% reduction in the risk of recurrence or death.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.